$1.54
0.65% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US15117K1034
Symbol
CLLS
Sector
Industry

Cellectis SA Sponsored ADR Stock price

$1.54
+0.16 11.59% 1M
-0.37 19.37% 6M
-0.26 14.44% YTD
-1.43 48.15% 1Y
-2.24 59.26% 3Y
-18.01 92.12% 5Y
-29.11 94.98% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.01 0.65%
ISIN
US15117K1034
Symbol
CLLS
Sector
Industry

Key metrics

Market capitalization $111.02m
Enterprise Value $-23.85m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales -0.50
P/S ratio (TTM) P/S ratio 2.33
P/B ratio (TTM) P/B ratio 1.33
Revenue growth (TTM) Revenue growth 825.97%
Revenue (TTM) Revenue $47.63m
EBIT (operating result TTM) EBIT $-65.84m
Free Cash Flow (TTM) Free Cash Flow $25.61m
Cash position $243.69m
EPS (TTM) EPS $-0.63
P/E forward negative
P/S forward 2.73
EV/Sales forward negative
Short interest 0.39%
Show more

Is Cellectis SA Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Cellectis SA Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Cellectis SA Sponsored ADR forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Cellectis SA Sponsored ADR forecast:

Buy
71%
Hold
29%

Financial data from Cellectis SA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
48 48
827% 827%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses - -
- Research and Development Expense 80 80
10% 10%
168%
-46 -46
47% 47%
-96%
- Depreciation and Amortization 20 20
8% 8%
42%
EBIT (Operating Income) EBIT -66 -66
37% 37%
-138%
Net Profit -61 -61
7% 7%
-127%

In millions USD.

Don't miss a Thing! We will send you all news about Cellectis SA Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cellectis SA Sponsored ADR Stock News

Positive
Seeking Alpha
6 days ago
Cellectis SA's pipeline consists of allogeneic CAR T-cell therapies that have the potential to make meaningful dents in heme malignancies. The financial picture remains strong, bolstered further by a partnership with AstraZeneca. Promised data readouts in late 2025 represent important potential catalysts.
Neutral
GlobeNewsWire
8 days ago
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided financial results for the first quarter 2025, ending March 31, 2025, and provided a business update.
Neutral
GlobeNewsWire
14 days ago
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market.
More Cellectis SA Sponsored ADR News

Company Profile

Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

Head office France
CEO André Choulika
Employees 222
Founded 1999
Website www.cellectis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today